The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy

Mol Cancer. 2021 Sep 8;20(1):116. doi: 10.1186/s12943-021-01406-7.

Abstract

Cancer immunotherapy has recently shown promising antitumor effects in various types of tumors. Among all immune checkpoints, the PD-1/PD-L1 pathway plays an important role in the immune evasion of tumor cells, making it a potent target in antitumor immunity. Accordingly, antibodies targeting the PD-1/PD-L1 pathway have been developed to attack tumor cells; however, resistance to immune therapy remains to be solved. Hence, identification of the underlying modulators of the PD-1/PD-L1 pathway is of significant importance to understand the mechanisms of antitumor immunotherapy. Long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) have been identified to regulate the PD-1/PD-L1 pathway, leading to participation in the immune response and immunotherapy. Therefore, this review focuses on the functions of lncRNAs and circRNAs in regulation of the PD-1/PD-L1 axis in tumorigenesis and tumor progression. We hope this review will stimulate research to supply more precise and effective cancer immune checkpoint therapies for a large number of tumors.

Keywords: Cancer; CircRNAs; Immunotherapy; LncRNAs; PD-1; PD-L1.

Publication types

  • Review

MeSH terms

  • Animals
  • B7-H1 Antigen / metabolism*
  • Biomarkers, Tumor
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Immunotherapy / methods
  • Neoplasms / diagnosis
  • Neoplasms / etiology
  • Neoplasms / metabolism
  • Neoplasms / therapy
  • Programmed Cell Death 1 Receptor / metabolism*
  • RNA Interference
  • RNA, Circular*
  • RNA, Long Noncoding*
  • Signal Transduction*

Substances

  • B7-H1 Antigen
  • Biomarkers, Tumor
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • RNA, Circular
  • RNA, Long Noncoding